Bonnie H.  Anderson net worth and biography

Bonnie Anderson Biography and Net Worth

Insider of Veracyte
Bonnie H. Anderson has served as our co-founder, Chief Executive Officer and as a member of our board of directors since February 2008 and as the Chairman of our board of directors since December 2016. From August 2013 to February 2017, she also served as our President. Prior to joining us, Ms. Anderson was an independent strategic consultant from April 2006 to January 2008, including as a strategic consultant for us from July 2007 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. Ms. Anderson currently serves as a member of the board of directors of Bruker Corporation and as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson previously served as a member of the board of directors of Castle Biosciences, Inc. from June 2015 to August 2020. Ms. Anderson holds a B.S. in Medical Technology from Indiana University of Pennsylvania. 

What is Bonnie H. Anderson's net worth?

The estimated net worth of Bonnie H. Anderson is at least $945,810.96 as of April 14th, 2023. Ms. Anderson owns 42,681 shares of Veracyte stock worth more than $945,811 as of March 28th. This net worth approximation does not reflect any other investments that Ms. Anderson may own. Learn More about Bonnie H. Anderson's net worth.

How do I contact Bonnie H. Anderson?

The corporate mailing address for Ms. Anderson and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on Bonnie H. Anderson's contact information.

Has Bonnie H. Anderson been buying or selling shares of Veracyte?

Bonnie H. Anderson has not been actively trading shares of Veracyte in the last ninety days. Most recently, Bonnie H. Anderson sold 34,000 shares of the business's stock in a transaction on Friday, April 14th. The shares were sold at an average price of $22.04, for a transaction totalling $749,360.00. Following the completion of the sale, the director now directly owns 42,681 shares of the company's stock, valued at $940,689.24. Learn More on Bonnie H. Anderson's trading history.

Who are Veracyte's active insiders?

Veracyte's insider roster includes Bonnie Anderson (Insider), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Giulia Kennedy (Insider), and Marc Stapley (CEO & Director ). Learn More on Veracyte's active insiders.

Are insiders buying or selling shares of Veracyte?

In the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 51,432 shares worth more than $1,250,046.41. The most recent insider tranaction occured on July, 18th when Director John L Bishop sold 10,000 shares worth more than $305,000.00. Insiders at Veracyte own 2.6% of the company. Learn More about insider trades at Veracyte.

Information on this page was last updated on 7/18/2023.

Bonnie H. Anderson Insider Trading History at Veracyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/14/2023Sell34,000$22.04$749,360.0042,681View SEC Filing Icon  
3/15/2023Sell34,000$22.76$773,840.0053,967View SEC Filing Icon  
1/17/2023Sell34,000$26.35$895,900.0062,961View SEC Filing Icon  
1/11/2023Sell63,247$25.13$1,589,397.1162,961View SEC Filing Icon  
12/1/2022Sell80,000$28.26$2,260,800.0065,003View SEC Filing Icon  
9/17/2021Sell2,600$50.18$130,468.00View SEC Filing Icon  
9/10/2021Sell1,900$50.03$95,057.00View SEC Filing Icon  
1/12/2021Sell20,354$50.20$1,021,770.80268,938View SEC Filing Icon  
10/8/2020Sell50,000$38.00$1,900,000.00270,231View SEC Filing Icon  
9/10/2020Sell20,000$30.89$617,800.00240,231View SEC Filing Icon  
7/30/2020Sell11,365$32.24$366,407.60283,572View SEC Filing Icon  
7/23/2020Sell3,280$32.04$105,091.20275,487View SEC Filing Icon  
7/21/2020Sell3,447$32.09$110,614.23274,060View SEC Filing Icon  
6/10/2020Sell20,000$26.56$531,200.00292,207View SEC Filing Icon  
5/11/2020Sell20,000$26.67$533,400.00274,183View SEC Filing Icon  
3/10/2020Sell20,000$25.18$503,600.00276,313View SEC Filing Icon  
1/10/2020Sell20,000$28.86$577,200.00137,738View SEC Filing Icon  
11/15/2019Sell20,000$25.06$501,200.00123,726View SEC Filing Icon  
10/10/2019Sell8,000$24.50$196,000.00109,467View SEC Filing Icon  
9/10/2019Sell8,000$24.51$196,080.00111,028View SEC Filing Icon  
8/12/2019Sell8,000$25.28$202,240.00121,414View SEC Filing Icon  
7/10/2019Sell8,000$28.79$230,320.00127,955View SEC Filing Icon  
6/10/2019Sell8,000$26.33$210,640.00127,955View SEC Filing Icon  
5/10/2019Sell8,000$22.99$183,920.00103,292View SEC Filing Icon  
4/10/2019Sell8,000$25.39$203,120.00103,292View SEC Filing Icon  
3/11/2019Sell8,000$19.97$159,760.00110,592View SEC Filing Icon  
2/26/2019Sell20,000$20.94$418,800.00View SEC Filing Icon  
2/11/2019Sell8,000$18.17$145,360.0084,541View SEC Filing Icon  
1/10/2019Sell25,500$15.29$389,895.0094,041View SEC Filing Icon  
12/10/2018Sell8,000$12.13$97,040.0059,236View SEC Filing Icon  
11/12/2018Sell23,305$13.42$312,753.1075,846View SEC Filing Icon  
8/27/2018Sell6,000$12.00$72,000.0058,541View SEC Filing Icon  
8/2/2018Sell14,950$11.50$171,925.0067,491View SEC Filing Icon  
7/23/2018Sell6,000$10.20$61,200.0058,541View SEC Filing Icon  
6/25/2018Sell6,000$9.26$55,560.0057,627View SEC Filing Icon  
6/12/2018Sell12,000$8.00$96,000.00View SEC Filing Icon  
10/20/2017Sell16,000$9.41$150,560.0016,000View SEC Filing Icon  
10/18/2017Sell6,000$9.09$54,540.0016,000View SEC Filing Icon  
9/25/2017Sell6,000$8.44$50,640.0016,000View SEC Filing Icon  
3/21/2017Sell5,000$9.09$45,450.0015,000View SEC Filing Icon  
6/3/2016Buy5,000$5.40$27,000.007,500View SEC Filing Icon  
6/1/2016Buy5,000$5.46$27,300.002,500View SEC Filing Icon  
5/31/2016Buy2,500$5.46$13,650.002,500View SEC Filing Icon  
6/27/2014Sell1,000$17.95$17,950.00View SEC Filing Icon  
6/23/2014Sell4,000$16.45$65,800.00View SEC Filing Icon  
See Full Table

Bonnie H. Anderson Buying and Selling Activity at Veracyte

This chart shows Bonnie H Anderson's buying and selling at Veracyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veracyte Company Overview

Veracyte logo
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $22.16
Low: $21.56
High: $22.35

50 Day Range

MA: $23.91
Low: $21.00
High: $27.09

2 Week Range

Now: $22.16
Low: $19.52
High: $30.52

Volume

614,310 shs

Average Volume

632,451 shs

Market Capitalization

$1.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64